The Global Liver Cirrhosis Treatment Market in Terms of Revenue Was Worth of USD 4.27 Billion in 2020 and is expected to reach USD 8.17 Billion in 2027, growing at a CAGR of 9.97% from 2021 to 2027. The global liver cirrhosis treatment market is expected to grow at a significant growth rate due to several driving factors.
Cirrhosis is the last stage of liver skin injury that results from a variety of conditions such as liver disease, hepatitis, acute alcoholism, iron buildup in the body (hemochromatosis), cystic fibrosis, copper accumulated in the liver (wilson's disease), poorly formed bile ducts (biliary atresia), alpha-1 antitrypsin deficiency, Inherited disorders of sugar metabolism (galactosemia or glycogen storage disease), genetic digestive disorder (alagille syndrome) and others. It is an acute stain of the liver and hepatic impairment that appears in the terminal stage of acute liver disease. This stain is most likely caused by prolonged exposure to a virus, such as alcohol or a viral infection. Also, the treatment of cirrhosis depends on the cause and extent of the loss.
The goal of this treatment is to slow the progression of scar tissue in the liver and to prevent or treat the symptoms and complications of cirrhosis. Furthermore, the treatment of cirrhosis is highly variable depending on the severity of the liver deterioration and includes prevention of further liver damage, treatment of cirrhosis complications, early diagnosis of liver cancer, or others. Liver transplantation may be the only treatment option when the liver stops working in advanced cases of cirrhosis. Liver transplantation is the process of replacing the liver with a dead donor or a living donor on one side of the liver. The most common cause of liver transplantation is cirrhosis.
The study provides a crucial view of the global liver cirrhosis treatment market by segmenting the market based on treatment, end-user, and region & country level. Based upon treatment, liver cirrhosis treatment market is segmented into antibiotics, immunosuppressants, and others. Based upon end-user, liver cirrhosis treatment market is segmented into hospitals and clinics, research and academic institutes and others. The regions covered in the global liver cirrhosis treatment market are North America, Europe, Asia-Pacific, and the Rest of the World. Based on the country level, the global liver cirrhosis treatment market is sub-divided into U.S., Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Brazil, Mexico, GCC, Africa, etc.
The growing aging population, excessive alcohol consumptions, and increasing prevalence of liver diseases are the major factors driving the market growth. In the recent years, the changing lifestyle is a major factor increasing the alcohol consumption. For example; According to the 2019 National Survey on Drug Use and Health; 14.1 million adults ages 18 and older had alcohol use disorder. This includes 8.9 million men and 5.2 million women. Additionally, they estimated 95,000 people die from alcohol-related causes annually. In addition, growing aging population is also one of the major factors driving the growth of global liver cirrhosis treatment market. The increasing aging population is a worldwide issue and societies are facing various problems including long-term care for populations with a high prevalence of chronic conditions including liver diseases. However, stringent government regulations, high investment required for drug research and development, and side-effects associated with medications prescribed for liver cirrhosis may hamper the market growth. In spite of that, increasing research and development activities in the field of liver disease treatment may create several opportunities for the further growth of the market.
The treatment segment of the global liver cirrhosis treatment market is dominated by antibiotics with the largest market share of XX.XX% in 2020. The end-user segment of global liver disease treatment is dominated by hospitals and clinics with the largest share of 79.35 % in the year 2020.
North America region is expected to dominate the global liver cirrhosis treatment market owing to rapidly changing lifestyles and excessive consumption of alcohol, increasing geriatric population, and growing liver-related diseases in this region. Over the few years, the number of cases of liver cirrhosis treatment is increasing in this region. Americans’ alcohol consumption reached 7.8 billion gallons in 2018 according to the national institute on alcohol abuse and alcoholism. According to a national health interview survey; the number of adults diagnosed with liver disease is 4.5 million and the percent of adults with diagnosed liver disease is 1.8%. Also, Asia Pacific regions are expected to emerge as the fastest-growing regional market due to the increasing geriatric population and growing number of cases of liver diseases in this region. For example; according to the World Health Organization; some 350 million people worldwide are living infected by hepatitis B, and 75% live in the Asia Pacific region. In China alone, an estimated 90 million people, or 7% of its population, are infected by some chronic form of the virus.
If liver cirrhosis is diagnosed early, damage can be reduced by treating the underlying cause or the various complications that arise. It is necessary for the patient to stop drinking if their cirrhosis is caused by long-term, regular heavy alcohol consumption. Therefore, the therapist or doctor recommends a treatment program for treating alcohol dependency. Liver cirrhosis is a major and underestimated global public health problem as well as an important cause of morbidity and mortality around the world. Appropriate advanced diagnosis and required treatment with different molecules might help in understanding the overall operations of fibrogenesis which is the driving force of cirrhosis pathogenesis. Currently medical companies inventing some potential breakthrough treatments that could transform the way to treat liver cirrhosis and offer the potential to save many live. The economic costs for cirrhosis and chronic liver diseases are valued to be around 1.9 billion for liver cancer $1.3 billion. Some of the major trends in the global liver cirrhosis treatment market are:
Regenerative Medicine: Recent advancements in the area of regenerative medicine open up new breakthroughs and increases capability in the treatment of irreversibly damaged liver cirrhosis. Liver cirrhosis regenerative medicines are mainly focusing on introduction of new therapies to either functionally restore the chronically damaged liver tissue or to develop the new organ. Regeneration offers an excellent breakthrough in the development of liver regenerative medicine. Furthermore, regenerative medicines are less invasive and less expensive and avoid the problem of shortage of donors, immune rejection as compared to other therapies. More importantly, liver regenerative medicine seems an ultimate solution for liver cirrhosis. Liver cirrhosis regenerative medicines are mainly utilizing two approaches which are based on cell therapy and tissue or organ engineering. Cell based therapy refers as the transplantation of cells from different sources with or without differentiation to improve liver function.
Mainly cells are classified into two main types that are stem cells and mature hepatocytes are the potential cell-based therapies accepted increasingly in the cure and regeneration of liver cirrhosis. In addition, recently healthcare professionals shifting their focus on the establishment of personalized medicine and the replacement or regeneration of damaged tissue. To those requirements, stem cell‐based therapies might be proven as a strong platform. The robust properties of indefinite cell division and differentiation potential into other cell types have made it possible the stem cells as a popular choice for treatment and regeneration of liver cirrhosis.
Drug: According to new research study, drug therapy is offering good results and helps in treating serious life-threatening diseases associated with cirrhosis and other chronic liver diseases. Drug usage for etiology of liver cirrhosis revealed that tenofovir is one of the main antiviral agents for treatment of CHB. Tenofovir may have been preferred because it is highly potent and it’s relatively affordable for patients. Antibacterial agents are the most accepted prescribed therapeutic class of drugs for the treatment of liver cirrhosis.
Cell Based Treatment: Cell based therapy is the most valuable and efficient approaches to cure liver cirrhosis cases. Stem cell-based therapy is emerged as a milestone category with establishment from clinical studies. Various stem cells such as MSCs, HSCs, EPCs, ESCs, and iPSCs have been utilized for their good feasibility and clinical potentials. Out of which MSCs have been mostly studied, MSC are rarer population in bone marrow compared to HSCs which re capable of self-renewal and differentiation into HLCs as well as cell types of mesenchymal origin. Conventionally, MSCs have often isolated from bone marrow, but it is prepared from much other tissue such as umbilical cord blood, adipose tissue, and placenta. There seems to be source-dependent differences among MSCs.
Furthermore, stem cell therapy has emerged as a promising treatment approach for a myriad of life-threatening diseases such as liver cirrhosis in recent years. On the other spectrum, cell-based therapies for liver cirrhosis have speedily progressed from preliminary laboratory and pre-clinical evaluations. Researchers studied that both residential and non-residential liver stem cells have the ability to differentiate into hepatocyte-like cells or bile duct epithelial cells and can restore liver function. But still mechanistic action of stem cell-mediated restoration of liver function in liver cirrhosis has not been completely described.
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2027|
|Market Size in 2020:||USD 4.27 Billion|
|Base year considered||2020|
|Forecast Period CAGR %:||9.97 %|
|Market Size Expected in 2027:||USD 8.17 Billion|
|Tables, Charts & Figures:||175|
Gilead Sciences, Inc., Shionogi & Co., Ltd., Sanofi, British Biologicals, Hoffmann-La Roche Ltd., Merck & Co., Inc., Others
|Segments Covered||By Treatment, By End User|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|
Middle East and Africa